Literature DB >> 17967880

Cancer-causing mutations in a novel transcription-dependent nuclear export motif of VHL abrogate oxygen-dependent degradation of hypoxia-inducible factor.

Mireille Khacho1, Karim Mekhail, Karine Pilon-Larose, Josianne Payette, Stephen Lee.   

Abstract

It is thought that degradation of nuclear proteins by the ubiquitylation system requires nuclear-cytoplasmic trafficking of E3 ubiquitin ligases. The von Hippel-Lindau (VHL) tumor suppressor protein is the substrate recognition component of a Cullin-2-containing E3 ubiquitin ligase that recruits hypoxia-inducible factor (HIF) for oxygen-dependent degradation. We demonstrated that VHL engages in nuclear-cytoplasmic trafficking that requires ongoing transcription to promote efficient HIF degradation. Here, we report the identification of a discreet motif, DXGX(2)DX(2)L, that directs transcription-dependent nuclear export of VHL and which is targeted by naturally occurring mutations associated with renal carcinoma and polycythemia in humans. The DXGX(2)DX(2)L motif is also found in other proteins, including poly(A)-binding protein 1, to direct its transcription-dependent nuclear export. We define DXGX(2)DX(2)L as TD-NEM (transcription-dependent nuclear export motif), since inhibition of transcription by actinomycin D or 5,6-dichlorobenzimidazole abrogates its nuclear export activity. Disease-causing mutations of key residues of TD-NEM restrain the ability of VHL to efficiently mediate oxygen-dependent degradation of HIF by altering its nuclear export dynamics without affecting interaction with its substrate. These results identify a novel nuclear export motif, further highlight the role of nuclear-cytoplasmic shuttling of E3 ligases in degradation of nuclear substrates, and provide evidence that disease-causing mutations can target subcellular trafficking.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967880      PMCID: PMC2223288          DOI: 10.1128/MCB.01044-07

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  62 in total

1.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis.

Authors:  P H Maxwell; M S Wiesener; G W Chang; S C Clifford; E C Vaux; M E Cockman; C C Wykoff; C W Pugh; E R Maher; P J Ratcliffe
Journal:  Nature       Date:  1999-05-20       Impact factor: 49.962

2.  C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation.

Authors:  A C Epstein; J M Gleadle; L A McNeill; K S Hewitson; J O'Rourke; D R Mole; M Mukherji; E Metzen; M I Wilson; A Dhanda; Y M Tian; N Masson; D L Hamilton; P Jaakkola; R Barstead; J Hodgkin; P H Maxwell; C W Pugh; C J Schofield; P J Ratcliffe
Journal:  Cell       Date:  2001-10-05       Impact factor: 41.582

3.  A short amino acid sequence able to specify nuclear location.

Authors:  D Kalderon; B L Roberts; W D Richardson; A E Smith
Journal:  Cell       Date:  1984-12       Impact factor: 41.582

4.  Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.

Authors:  P Jaakkola; D R Mole; Y M Tian; M I Wilson; J Gielbert; S J Gaskell; A von Kriegsheim; H F Hebestreit; M Mukherji; C J Schofield; P H Maxwell; C W Pugh; P J Ratcliffe
Journal:  Science       Date:  2001-04-05       Impact factor: 47.728

5.  HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation.

Authors:  F Yu; S B White; Q Zhao; F S Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells.

Authors:  Lakshman Gunaratnam; Melissa Morley; Aleksandra Franovic; Natalie de Paulsen; Karim Mekhail; Doris A E Parolin; Eijiro Nakamura; Ian A J Lorimer; Stephen Lee
Journal:  J Biol Chem       Date:  2003-08-27       Impact factor: 5.157

Review 7.  Oxygen sensing by H+: implications for HIF and hypoxic cell memory.

Authors:  Karim Mekhail; Mireille Khacho; Lakshman Gunaratnam; Stephen Lee
Journal:  Cell Cycle       Date:  2004-08-07       Impact factor: 4.534

8.  HIF activation by pH-dependent nucleolar sequestration of VHL.

Authors:  Karim Mekhail; Lakshman Gunaratnam; Marie-Eve Bonicalzi; Stephen Lee
Journal:  Nat Cell Biol       Date:  2004-06-06       Impact factor: 28.824

9.  Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions.

Authors:  Catherine Gallou; Dominique Chauveau; Stéphane Richard; Dominique Joly; Sophie Giraud; Sylviane Olschwang; Natacha Martin; Céline Saquet; Yves Chrétien; Arnaud Méjean; Jean-Michel Correas; Gérard Benoît; Pierre Colombeau; Jean-Pierre Grünfeld; Claudine Junien; Christophe Béroud
Journal:  Hum Mutat       Date:  2004-09       Impact factor: 4.878

Review 10.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

View more
  4 in total

Review 1.  Nuclear-cytoplasmatic shuttling of proteins in control of cellular oxygen sensing.

Authors:  Reinhard Depping; Wolfgang Jelkmann; Friederike Katharina Kosyna
Journal:  J Mol Med (Berl)       Date:  2015-03-27       Impact factor: 4.599

2.  eEF1A is a novel component of the mammalian nuclear protein export machinery.

Authors:  Mireille Khacho; Karim Mekhail; Karine Pilon-Larose; Arnim Pause; Jocelyn Côté; Stephen Lee
Journal:  Mol Biol Cell       Date:  2008-09-17       Impact factor: 4.138

3.  Role of Ran-regulated nuclear-cytoplasmic trafficking of pVHL in the regulation of microtubular stability-mediated HIF-1α in hypoxic cardiomyocytes.

Authors:  Xupin Jiang; Dongxia Zhang; Hengshu Zhang; Yuesheng Huang; Miao Teng
Journal:  Sci Rep       Date:  2015-03-17       Impact factor: 4.379

4.  Proteome-wide search for functional motifs altered in tumors: Prediction of nuclear export signals inactivated by cancer-related mutations.

Authors:  Gorka Prieto; Asier Fullaondo; Jose A Rodríguez
Journal:  Sci Rep       Date:  2016-05-12       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.